Online Inquiry
Cat.#: ASSD-121
| Description | Fluorescent A3 adenosine receptor antagonist. Displays selectivity for A3 over A2A and A1 (apparent KD values are 8.10, 6.74 and 6.57 respectively). Antagonizes the activity of NECA, an adenosine receptor agonist. Exhibits no intrinsic agonist activity. A fluorescent Xanthine Amine Congener (XAC) analog. |
| Synonyms | Fluorescent Adenosine A3 receptor Antagonist (A3-633-AN), A3-633-AN |
| Size | 500 μg |
| Applications | For ligand binding; fluorescence imaging; high content analysis; kinetic analysis; cell sorting at adenosine A1 / A2A / A3 receptors use solutions up to 100 nM. |
| Molecule Weight | 1144 |
| Purity | >95% |
| Solubility | Soluble in DMSO |
| Form | Purple solid |
| Excitation | 633 nm |
| Emission | 650 nm |
| Storage | Store at -20° C(protect from light) |
| Shipping | Shipped at 4°C |
| Important | We recommend briefly sonicating the sample when using to ensure it is fully dissolved and the solution is homogeneous. However, we do not recommend using the product after subjecting it to repetitive freeze-thaw cycles. |
| Cat.# | Name | Size | Price |
|---|---|---|---|
| ASSD-218 | 6-Carboxy-2′,7′-dichlorofluorescein-3′,6′-diacetatesuccinimidyl Ester (AC218) | 25 mg | inquiry |
| ASSD-186 | Bromocresol Purple (AC186) | 5 g, 10 g | inquiry |
| ASSD-228 | ImmunoHistoMount (AC228) | 30 ml | inquiry |
| ASSD-151 | Acid Fuchsin (AC151) | 25 g | inquiry |
| ASSD-212 | 5(6)-Carboxy-2′,7′-dichlorofluorescein diacetate N-succinimidyl ester (AC212) | 25 mg | inquiry |
| ASSD-170 | BAPTA-AM (AC170) | 25 mg | inquiry |
| ASSD-173 | FITC-Dextran 70 (AC173) | 100 mg, 500 mg | inquiry |
| ASSD-116 | Annexin V-FITC Apoptosis Staining / Detection Kit (AC116) | 1 kit, 100 tests | inquiry |
| ASSD-127 | Fluorescent H3 antagonist [clobenpropit] (AC127) | 50 μg | inquiry |
| ASSD-227 | Organo/Limonene Mount (AC227) | 100 ml | inquiry |
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.